NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
AWS Bahrain Region Disrupted by Drone Activity Amid Middle East Conflict 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
SAN ANTONIO, Texas, May 03, 2017 -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the EPO patent for bioAffinity’s platform test for early cancer detection will significantly increase bioAffinity’s intellectual property (IP) portfolio that currently consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by flow cytometry. CyPath® Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by patients at risk for lung cancer.
“According to the World Health Organization, nearly 30 percent of European adults are smokers, and smoking among adolescents is on the rise,” bioAffinity President and CEO Maria Zannes said. “Tobacco use causes 16 percent of all deaths in the adult population over 30 years of age. We expect our CyPath® product to have a significant positive impact on early detection of lung cancer in the European Union.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath® Lung is a simple and cost-effective diagnostic, which will make it particularly valuable in countries with large populations and broad economic and social demographics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
